Pediatric antifungal agents

Current Opinion in Infectious Diseases

Volumn 22, Issue 6, 2009, Pages 553-558

  Cohen Wolkowiez, Michael ^a   Moran, Cassandra ^a   Benjamin, Daniel K ^a   Smith, Phillip B ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Child; Immunocompromised host; Infant; Mycoses; Neutropenia

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

ASPERGILLOSIS; CANDIDIASIS; CHILD; CLINICAL TRIAL; CRYPTOCOCCAL MENINGITIS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; ESOPHAGUS CANDIDIASIS; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION PREVENTION; INVASIVE CANDIDIASIS; LIVER FUNCTION TEST; LOADING DRUG DOSE; MORTALITY; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; OROPHARYNX CANDIDIASIS; PERIPHERAL EDEMA; RECOMMENDED DRUG DOSE; RETINA DISEASE; REVIEW; SIDE EFFECT; VISUAL DISORDER;

AGE FACTORS; ANTIFUNGAL AGENTS; CHILD; ECHINOCANDINS; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; MYCOSES;

EID: 70350521751     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283321ccc     Document Type: Review

References (71)

1. Atkinson AJ Jr, Bennett JE. Amphotericin B pharmacokinetics in humans. Antimicrob Agents Chemother 1978; 13:271-276.
2. Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neo-nates. J Pediatr 1990; 116:791-797.
3. Luna B, Drew RH, Perfect JR. Agents for treatment of invasive fungal infections. Otolaryngol Clin North Am 2000; 33:277-299.
4. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12:308-329.
5. Dismukes WE. Introduction to antifungal agents. Clin Infect Dis 2000; 30:653-657.
6. Al Arishi H, Frayha HH, Kalloghlian A, et al. Liposomal amphotericin B in neonates with invasive candidiasis. Am J Perinatol 1998; 15:643-648.
7. Klepser ME, Wolfe EJ, Jones RN, et al. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albi-cans. Antimicrob Agents Chemother 1997; 41:1392-1395.
8. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs 2001; 61 (Suppl 1):27-37.
9. Kaufman D, Boyle R, Hazen KC, et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001; 345:1660-1666.
10. Manzoni P, Stolfi I, Pugni L, et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007;356:2483-2495.
11. Benjamin DK Jr. First, do no harm. Pediatrics 2008; 121:831-832.
12. Wildfeuer A, Laufen H, Schmalreck AF, et al. Fluconazole: comparison of pharmacokinetics, therapy, and in vitro susceptibility. Mycoses 1997; 40: 259-265.
13. Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 1994; 13:325-329
14. Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother 2008; 52:4043-4049.
15. Novelli V, Holzel H. Safety and tolerability of fluconazole in children. Antimicrob Agents Chemother 1999; 43:1955-1960.
16. Groll AH, Wood L, Roden M, et al. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002; 46:2554-2563.
17. Grigull L, Kuehlke O, Beilken A, et al. Intravenous and oral sequential itraconazole antifungal prophylaxis in paediatric stem cell transplantation recipients: a pilot study for evaluation of safety and efficacy. Pediatr Transplant 2007; 11:261-266.
18. Heykants J, Van de Valde V, Van Rooy P. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 1989; 32:67-87.
19. de Repentigny L, Ratelle J, Leclerc J-M, et al. Repeated-dose pharmacokinetic of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 1998; 42:404-408.
20. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42:741-745.
21. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415. (Pubitemid 34851833)
22. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21:240-248.
23. Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocumpromised patients. Clin Infect Dis 2001; 33:1447-1454.
24. Frankenbusch K, Eifinger F, Kribs A, et al. Severe primary cutaneous aspergillosis refractory to amphotericin B and the successful treatment with systemic voriconazole in two premature infants with extremely low birth weight. J Perinatol 2006; 26:511-514.
25. Purkins L, Wood N, Ghahramani P, et al. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46:2546-2553.
26. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single-or multiple-dose administration. Antimicrob Agents Chemother 2004; 48:2166-2172.
27. Ghannoum MA, Kuhn DM. Voriconazole: better chances for patients with invasive mycoses. Eur J Med Res 2002; 7:242-256.
28. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 2009; 53:935-944.
29. Segal BH, Barnhart LA, Anderson VL, et al. Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection. Clin Infect Dis 2005; 40:1684-1688.
30. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005; 45:185-192.
31. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47:2788-2795.
32. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57:218-222.
33. Krishna G, AbuTarif M, Xuan F, et al. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 2008; 28:1223-1232.
34. Walsh TJ, Viviani MA, Arathoon E, et al. New targets and delivery systems for antifungal therapy. Medical Mycology 2000; 38 (Suppl 1):335-347.
35. Olsen SJ, Mummaneni V, Rolan P, et al. Ravuconazole single ascending oral dose study in healthy subjects. In: Program and Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000; Toronto, Ontario. Washington, DC.
36. Ernst EJ. Investigational antifungal agents. Pharmacotherapy 2001; 21:165S-175S.
37. Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 2001; 21 (8 Pt 2): 133S-148S.
38. Merlin E, Galambrun C, Ribaud P, et al. Efficacy and safety of caspofungin therapy in children with invasive fungal infections. Pediatr Infect Dis J 2006; 25:1186-1188.
39. CesaroS,GiacchinoM, Locatelli F, et al. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis 2007; 7:28.
40. KooA, Sung L, Allen U, et al. Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children. Pediatr Infect Dis J 2007; 26:854-856.
41. Zaoutis TE, Jafri HS, Huang LM, et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009; 123:877-884.
42. Natarajan G, Lulic-Botica M, Rongkavilit C, et al. Experience with caspofungin in the treatment of persistent fungemia in neonates. J Perinatol 2005; 25:770-777.
43. Odio CM, Araya R, Pinto LE, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004; 23:1093-1097.
44. Graybill JR. The echinocandins, first novel class of antifungals in two decades: will they live up to their promise? Int J Clin Pract 2001; 55:633-638.
45. Stone JA, Holland SD, Wickersham PJ, et al. Single-and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739-745
46. Stone J, Holland S, Li S, et al. Effect of hepatic insufficiency on the pharmacokinetics of caspofungin. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 16-19 December 2001; Chicago, Illinois. Washington, DC.
47. Sable CA, Nguyen B-YT, Chodakewitz JA, et al. Safety and tolerability of caspofungin acetate in the treatment of fungal infections. Transpl Infect Dis 2002; 4:25-30.
48. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49:4536-4545.
49. Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009; 53:1450-1456
50. Saez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009; 53:869-875.
51. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44:57-62.
52. Kohno S, Masaoka T, Yamaguchi H. A multicenter, open-label clinical study of FK463 in patients with deep mycoses in Japan. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 16-19 December 2001; Chicago, Illinois. Washington, DC.
53. Ratanatharathorn V, Flynn P, Van Burik JA, et al. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients. In: Program and Abstracts of the American Society of Hematology 44th Annual Meeting; 6-10 December 2002; Philadelphia. Washington, DC.
54. Van BurikJ, Ratanatharathorn V, Lipton J, et al. Randomized, double-blind trial of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant, NIAID/BAMSG protocol 46. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2002; San Diego. Washington, DC.
55. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis: substudy of a randomized double-blind trial. Pediatr Infect Dis J 2008; 27:820-826.
56. Okugawa S, Ota Y, Tatsuno K, et al. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. Scand J Infect Dis 2007; 39:344-346.
57. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008; 197:163-171.
58. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49:3317-3324
59. Hope WW, Seibel NL, Schwartz CL, et al. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother 2007; 51:3714-3719.
60. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006; 25:1110-1115.
61. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009; 28:412-415.
62. Benjamin Jr. DK, Smith P, Arrieta A, et al. Safety and pharmacokinetics of repeat-dose micafungin in neonates. In: Program and Abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008; Washington, DC. Micafungin FDA label. Food and Drug Administration, 2005; http://www.fda.gov.
63. Pfaller MA, Diekema DJ, Boyken L, et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother 2005; 49:4795-4797.
64. Vazquez JA, Schranz JA, Clark K, et al. A phase 2, open-label study of the safety and efficacy of intravenous anidulafungin as a treatment for azole-refractory mucosal candidiasis. J Acquir Immune Defic Syndr 2008; 48:304-309.
65. Reboli AC, Rotstein C, PappasPG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-2482.
66. Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42:2898-2905.
67. Lucas R, De Sante K, Hatcher B, et al. LY303366 single dose pharmacokinetics and safety in healthy volunteers. In: Program and Abstracts of the 36th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 1996; New Orleans. Washington, DC.
68. Dowell JA, Stogniew M, Krause D, et al. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment. J Clin Pharmacol 2007; 47:461-470.
69. Benjamin DKJ, Driscoll T, Seibel NL, et al. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50:632-638.
70. Cohen-Wolkowiez M, Smith P, Piper L, et al. Safety and pharmacokinetics of multiple dose anidulafungin in infants. In: Program and Abstracts of the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; 2009; San Francisco, California.
71. Thye D, Shepherd B, White RJ, et al. Anidulafungin: a phase 1 study to identify the maximum tolerated dose in healthy volunteers. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 16-19 December 2001; Chicago, Illinois. Washington, DC.